Sotorasib and Panitumumab Combination Extends Survival in Phase 3 Trial for Specific Patient Population.

A recent Phase 3 clinical trial indicated that patients treated with a combination of sotorasib and panitumumab experienced increased survival times. The study investigated the efficacy of this drug combination in a specific patient population. The trial results showed that individuals who received both sotorasib and panitumumab lived longer compared to those who did not. The study focused on patients in a Phase 3 clinical trial setting, allowing for a rigorous assessment of the treatment’s impact on survival.

Newsflash | Powered by GeneOnline AI
Date: April 24, 2025

Author

Mark Chiang